Data Sheet (Cat.No.T78875)

TargetMol

BTM-3528

Chemical Properties



CAS No. : 2054998-45-5

Formula: C24H19F4N3O2S2

Molecular Weight: 521.55

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	BTM-3528 is an activator of the mitochondrial protease OMA1 with anticancer activity. BTM-3528 activates the ISR via the mitochondrial protease OMA1, inducing OMA1-dependent cleavage of DELE1 and OPA1 and mitochondrial fragmentation.BTM-3528 induces cell growth arrest and apoptosis.
Targets(IC50)	Apoptosis,Mitochondrial Metabolism,PERK
In vitro	Both BTM-3528 and BTM-3566 demonstrated potent, dose-dependent activity against DLBCL lines of varying genotypes, including MYC-rearranged (“double” and “triple” hit) lymphomas, with growth inhibition and IC >90%50 values of 0.16–0.57 μmol/L. [2]
In vivo	**METHODS**: BTM-3566 was tested in 9 human DLBCL patient-derived xenograft (PDX) models representing ABC and GCB DLBCL subtypes, treated with 20 mg/kg BTM-3566. **RESULTS**: All 3 mice in 6 of the 9 PDX models achieved CR, and when 27 mice from the treatment groups across the 9 models were combined, CR was observed in 66% (19/27), with an additional 4 mice experiencing partial remission (PR), 2 mice experiencing stable tumors, and 2 experiencing progressive disease. [2]

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9174 mL	9.5868 mL	19.1736 mL
5 mM	0.3835 mL	1.9174 mL	3.8347 mL
10 mM	0.1917 mL	0.9587 mL	1.9174 mL
50 mM	0.0383 mL	0.1917 mL	0.3835 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Schwarzer A, et al. Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMAMol Cancer Ther. 2023 Nov 1;22(11):1290-1303.
Schwarzer A, et al. Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1. Mol Cancer Ther. 2023 Nov 1;22(11):1290-1303.